ELECTROCHEMICAL SENSOR FOR SIMULTANEOUS DETECTION OF DOPAMINE AND SEROTONIN AND MANUFACTURING METHOD THEREOF
20230400430 · 2023-12-14
Assignee
Inventors
Cpc classification
A61B5/1468
HUMAN NECESSITIES
G01N27/48
PHYSICS
G01N27/3275
PHYSICS
International classification
G01N27/327
PHYSICS
G01N27/48
PHYSICS
Abstract
The present disclosure relates to an electrochemical sensor for simultaneous detection of dopamine and serotonin including an electrode containing a reduced graphene oxide (rGO), poly(3,4-ethylenedioxythiophene):poly(4-styrenesulfonate) (PEDOT:PSS), and Nafion, wherein the sensor has high interfacial conductivity and electrocatalytic properties and further improves the negatively charged electrode interface, thereby enabling high sensitivity selective measurement of dopamine and serotonin. In addition, since the sensor according to the present disclosure is stable for a long time and has high reproducibility, it can be used for clinical diagnosis of various brain and neurological diseases, drug treatment, biological research using changes in the concentration of neurotransmitters, and biochip application fields.
Claims
1. An electrochemical sensor for simultaneous detection of dopamine and serotonin comprising a working electrode containing: a reduced graphene oxide (rGO); poly(3,4-ethylenedioxythiophene):poly(4-styrenesulfonate) (PEDOT:PSS); and Nafion.
2. The electrochemical sensor of claim 1, wherein the reduced graphene oxide is one in which a graphene oxide deposited on a gold (Au) thin film is electrochemically reduced.
3. The electrochemical sensor of claim 1, wherein the reduced graphene oxide is one which is reduced at pH 3 to 5.
4. The electrochemical sensor of claim 1, wherein the reduced graphene oxide is one which is reduced through the application of cyclic voltammetry (CV) in a voltage range of −1.5 to 0 V.
5. The electrochemical sensor of claim 1, wherein the sensor further comprises: a counter electrode including a platinum (Pt) wire or a gold thin film; and a reference electrode including a silver/silver chloride (Ag/AgCl) or gold thin film.
6. The electrochemical sensor of claim 1, wherein the sensor is one capable of simultaneously detecting dopamine and serotonin selectively by lowering the signal of an interfering substance having a negative charge.
7. The electrochemical sensor of claim 6, wherein the interfering substance is any one or more selected from the group consisting of ascorbic acid (AA), uric acid (UA), glucose, epinephrine (EP), norepinephrine (NE), and combinations thereof.
8. A kit for simultaneous detection of dopamine and serotonin, the kit comprising the sensor of claim 1.
9. A neural electrode system for simultaneous detection of dopamine and serotonin, the neural electrode system comprising the sensor of claim 5.
10. The neural electrode system of claim 9, wherein the system is one in which pluralities of counter electrodes and reference electrodes paired with a plurality of working electrodes are disposed in proximity.
11. The neural electrode system of claim 9, wherein the system is one in which single counter electrode and reference electrode that share a plurality of working electrodes are disposed to be spaced apart from each other.
12. A method for manufacturing an electrochemical sensor for simultaneous detection of dopamine and serotonin, the method comprising the following steps of: (1) performing electrophoretic deposition of a graphene oxide (GO) on a gold (Au) thin film working electrode; (2) preparing a reduced graphene oxide (rGO) by electrochemically reducing the graphene oxide deposited on the gold thin film; (3) preparing PEDOT:PSS by electropolymerizing a mixed solution of EDOT and PPS on the prepared reduced graphene oxide; and (4) coating the prepared PEDOT:PSS with Nafion to prepare a working electrode.
13. The method of claim 12, wherein the step (2) is to reduce the graphene oxide-deposited gold thin film at pH 3 to 5.
14. The method of claim 12, wherein the step (2) is to reduce the graphene oxide-deposited gold thin film by cyclic voltammetry (CV) in a voltage range of −1.5 to 0 V.
15. The method of claim 12, wherein the mixed solution of EDOT and PPS in the step (3) is one having a concentration ratio of EDOT:PPS of 1:10.
16. The method of claim 12, wherein the sensor further comprises: a counter electrode including a platinum (Pt) wire; and a reference electrode including silver/silver chloride (Ag/AgCl).
17. A method for simultaneous detection of dopamine and serotonin, the method comprising the following steps of: (1) treating a biological sample isolated from an individual on the electrochemical sensor for simultaneous detection of dopamine and serotonin of claim 1; and (2) performing differential pulse voltammetry (DPV) on the sample-treated sensor at pH 6 to 8.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0045] These and/or other aspects, features, and advantages of the invention will become apparent and more readily appreciated from the following description of example embodiments, taken in conjunction with the accompanying drawings of which:
[0046]
[0047]
[0048]
[0049]
[0050]
[0051]
[0052]
[0053]
[0054]
DETAILED DESCRIPTION
[0055] Since the electrochemical sensor including an rGO/PEDOT:PSS/Nafion electrode according to the present disclosure is manufactured by simply electropolymerizing PEDOT:PSS on a reduced graphene oxide (rGO) prepared at an optimal pH, and coating negatively charged Nafion thereon, it exhibits significantly improved catalytic properties and high conduction properties for the electroactivity of multiple neurotransmitters.
[0056] In order to confirm the dopamine and serotonin detection efficacy of the sensor, the present inventors carried out electrochemical characterization through electrochemical impedance spectroscopy (EIS), cyclic voltammetry (CV), and differential pulse voltammetry (DPV), and investigated the surface morphology, chemical state, and elemental composition of the electrode using a scanning electron microscope (SEM), Fourier-transform infrared (FT-IR) spectroscopy, Raman spectra, and high-resolution X-ray photoelectron spectroscopy (XPS).
[0057] As a result, it was confirmed that the electrochemical sensor including an rGO/PEDOT:PSS/Nafion electrode according to the present disclosure is capable of simultaneous high-sensitivity and selective detection of dopamine and serotonin by high affinity for cations.
[0058] Specifically, as a result of the electrochemical reaction, well-separated oxidation peaks were observed for mixtures containing various concentrations of dopamine and serotonin, and the dynamic sensing concentration ranges of dopamine and serotonin were shown to be 0.5 to 75 μM and 0.05 to 50 μM, respectively, and the detection limits were shown to be 0.5 and 0.05 μM, respectively. In the mixtures of dopamine and serotonin, the detection limits of dopamine and serotonin were 0.1 μM, and the sensitivities thereof were 99.3 and 86 μA/Mcm.sup.2, respectively. Moreover, the electrochemical sensor according to the present disclosure exhibited high selectivity, reproducibility, stability, and recovery rate in the human serum spike test.
[0059] Accordingly, the present disclosure provides an electrochemical sensor for simultaneous detection of dopamine and serotonin, including; a working electrode including a reduced graphene oxide (rGO), PEDOT:PSS, and Nafion; a counter electrode including a platinum (Pt) wire; and a reference electrode including silver/silver chloride (Ag/AgCl).
[0060] In the present disclosure, the “working electrode” refers to an electrode in which a reaction of interest occurs in an electrochemical experimental system, may also be referred to as a cathode or anode depending on whether the reaction occurring at the electrode is an oxidation reaction or a reduction reaction, and may be substituted for a “working electrode” and used. Non-limiting examples of the material of the working electrode may be metals such as copper, platinum, silver, gold, palladium, ruthenium, rhodium, and iridium, semiconductors such as carbon, GaAs, CdS, and In.sub.2O.sub.3, or materials with surface treatment for each material, but may be preferably a gold electrode. In the present disclosure, electrophoretic deposition of GO was simply performed on a gold (Au) thin film, reduction was performed in an optimal pH buffer medium to form an rGO, then electropolymerization was performed with EDOT:PSS to form PEDOT:PSS, and PEDOT:PSS was coated with Nafion to prepare a working electrode in which rGO/PEDOT:PSS/Nafion was patterned.
[0061] “PEDOT:PSS” refers to poly(3,4-ethylenedioxythiophene):poly(4-styrenesulfonate) known as a conductive polymer.
[0062] “Nafion” is a material having ion exchange properties, and is a kind of sulfonated tetrafluoroethylene based fluoropolymer-copolymer.
[0063] In the present disclosure, the “reference electrode” refers to an electrode that provides a reference potential, and for example, a potential difference, i.e., a voltage, may be established between the reference electrode and the working electrode.
[0064] In the present disclosure, the “counter electrode” refers to an electrode in an electrochemical circuit that acts as a current source or sink to complete the electrochemical circuit, and may be substituted for “a control electrode” and “a counter electrode” and used.
[0065] Further, the present disclosure provides a method for simultaneously detecting dopamine and serotonin from a biological sample isolated from an individual using the electrochemical sensor.
[0066] In the present disclosure, the “individual” is not limited as long as it is a mammal such as a livestock, a human, or the like, but may be preferably a human.
[0067] In the present disclosure, the “biological sample” is an analysis target for determining whether dopamine and/or serotonin is contained or not, or measuring the concentration, and may include all biological samples such as whole blood, blood cells, serum, plasma, bone marrow fluid, sweat, urine, tears, saliva, skin, mucosa, and the like, and may be preferably serum isolated from humans.
[0068] Further, the present disclosure provides an information providing method for diagnosing a brain-nervous system disease or a mental disease based on the concentrations of dopamine and serotonin measured using the electrochemical sensor.
[0069] In the present disclosure, the “brain-nervous system disease” may be Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, Pick disease, stroke, multiple system atrophy, dementia due to head trauma, vascular disease dementia, frontotemporal dementia (FTD), Corticobasal degeneration (CBD), Progressive supranuclear palsy (PSP), Lewy body dementia, tangle-predominant senile dementia, Argyrophilic grain disease, FTDP-17, Lytico-Bodig disease, learning disability, mild cognitive impairment, agnosia, forgetfulness, aphasia, apraxia, delirium, multiple sclerosis, brain cancer, traumatic brain injury (TBI), thrombosis, em-bolism, transient ischemic attack, lacune, cerebral apoplexy, cerebral infarction, cerebral circulatory metabolic disorder, brain function coma, or the like, but is not limited thereto.
[0070] In the present disclosure, the “mental disease” may be depression, lethargy, hyperactivity, attention deficit, autism, post-traumatic stress disorder (PTSD), anxiety disorder, sleep disorder, panic disorder, intellectual disability, memory loss, drug addiction, schizophrenia, obsessive compulsive disorder, megalomaniac, personality disorder, alcoholism, bipolar disorder, or the like, and may include physical symptoms resulting therefrom, for example, fatigue, indigestion, difficulty breathing, and the like, but is not limited thereto.
[0071] The terms used in the embodiments are used for the purpose of description only, and should not be construed as an intention to limit the present disclosure. The singular expression includes the plural expression unless the context clearly dictates otherwise. In the present specification, it should be understood that a term such as “comprise”, “have”, or the like is intended to designate that a feature, a number, a step, an operation, a component, a part, or a combination thereof described in the specification exists, but it does not preclude the possibility of existence or addition of one or more other features, numbers, steps, operations, components, parts, or combinations thereof.
[0072] Unless defined otherwise, all terms used herein, including technical or scientific terms, have the same meaning as those commonly understood by one of ordinary skill in the art to which the embodiments belong. Terms such as those defined in a commonly used dictionary should be interpreted as having a meaning consistent with the meaning in the context of the related art, and should not be interpreted in an ideal or excessively formal meaning unless explicitly defined in the present application.
[0073] The present disclosure can apply various transformations and can have various embodiments. Hereinafter, specific embodiments are illustrated in the drawings and described in detail in the detailed description. However, this is not intended to limit the present disclosure to specific embodiments, and should be understood to include all modifications, equivalents, and substitutes included in the spirit and technical scope of the present disclosure. In describing the present disclosure, if it is determined that a detailed description of a related known technology may obscure the gist of the present disclosure, the detailed description thereof will be omitted.
Experimental Example 1. Chemicals and Reagents
[0074] To fabricate the flexible sensor configuration, polyimide (PI, VTEC 1388) was obtained from Richard Blaine International, Inc., Philadelphia, PA, USA. DNR-L300-30 was obtained from Dongjin, Seoul, Korea. AZ 9260 was obtained from AZ Electronic Materials, NJ, USA. Phosphate buffer saline (0.1 M PBS, pH 7.4) was obtained from Duksan General Science in Korea.
[0075] For the electrochemical reduction, the phosphate buffer solution containing K.sub.2HPO.sub.4 and KH.sub.2PO.sub.4 was adjusted to the preferred pH. Dopamine (DA), serotonin (5-HT), ascorbic acid (AA), uric acid (UA), glucose, epinephrine (EP), and norepinephrine (NE) were purchased from Sigma-Aldrich for electrochemical analysis. Commercially-sterilized and filtered human serum (derived from human male AB plasma, USA origin, code H4522) was obtained from Sigma-Aldrich for spike testing.
Experimental Example 2. Fabrication of Flexible Sensor
[0076]
Experimental Example 3. Manufacturing of Flexible Sensor Including rGO/PEDOT:PSS/Nafion Electrode
[0077] As shown in
Experimental Example 4. Electrochemical Characterization
[0078] The electrochemical performance of the sensor according to one embodiment of the present disclosure was evaluated at room temperature by Autolab (PGSTAT 302N, NOVA software, Ecochemie, Utrecht, The Netherlands). Cyclic voltammetry (CV), electrochemical impedance spectroscopy (EIS), and differential pulse voltammetry (DPV) were performed using an Au reference electrode, an Au counter electrode, an Au (diameter of 2.4 mm) working electrode, and prepared GO-based working electrodes (GO, rGO, rGO/PEDOT:PSS, and rGO/PEDOT:PSS/Nafion).
[0079] CV with a potential limit of −0.2 to 0.8 V was performed at a scan rate of 100 mV/s, and the frequency range of EIS was 1 to 105 Hz. The parameters of the DPV measurement were set as follows: a scan rate of 25 mV/s, a pulse width of 0.06 seconds, and an amplitude of 30 mV. To avoid spontaneous oxidation of dopamine and serotonin, fresh solutions were prepared daily and stored in a dark room at 4° C. All experiments were performed at ambient temperature. The selectivity of the rGO/PEDOT:PSS/Nafion electrode was investigated via the DPV oxidation current response to serotonin (1 μM). At this time, ascorbic acid (AA, 1,000 μM), uric acid (UA, 50 μM), glucose (100 μM), epinephrine (EP, 10 μM), and norepinephrine (NE, 10 μM) was tested in a 0.1 M PBS (pH 7.4). The reproducibility of rGO/PEDOT:PSS/Nafion was investigated through six electrodes and serotonin oxidation peak current. At this time, in order to evaluate the reproducibility and selectivity of serotonin detection in the 0.1 M PBS (pH 7.4), DPV was calculated with 1 μM of serotonin (n=3).
Experimental Example 5. Surface Morphology and Elemental Analysis
[0080] The surface morphology and elemental analysis of the electrodes were evaluated with a scanning electron microscope (SEM, Regulus 8230). Fourier transform infrared (FT-IR) spectra were captured using a Thermo Nicolet iS10 spectrometer and pelleted in KBr for FT-IR analysis. Raman spectra were recorded using a Renishaw Raman microscope with a neodymium-doped yttrium aluminum garnet laser containing a photon beam of a wavelength of 532 nm. X-ray photoelectron spectroscopy (XPS, Ulvac, Japan) was irradiated with a monochromatic AI Kα, X-ray source. XPS distribution analysis (XPS depth profiling) was performed in order to obtain the approximate thickness of the layer. A high-energy Ar.sup.+ ion beam having an acceleration voltage of 2 kV was used to sputter samples layer by layer on the top surface within an area of 1×1 mm.sup.2. After each successive sputter cycle, Au4f, C1s, F1s, O1s and S2p peak areas were registered and analyzed.
Experimental Example 6. Serum Spiking Test
[0081] For practical validation of the sensor including the rGO/PEDOT:PSS/Nafion electrode for simultaneous detection of dopamine and serotonin, all serum samples were prepared without further processing or dilution. Various concentrations of dopamine and serotonin were tested in spiked serum samples. For quantitative analysis, the DPV current response of the sensor including the rGO/PEDOT:PSS/Nafion electrode was checked and compared with standard serotonin solution and serotonin spike serum through DPV. Current responses measured from spiked serum samples and standard solution that have various dopamine and serotonin concentrations were calculated and compared using recovery rate (% recovery rate=C.sub.i/C.sub.o/C.sub.x). At this time, C.sub.i and C.sub.o are the serotonin concentrations experimentally obtained in the spike and blank serum samples, respectively, and C.sub.x is the concentration of serotonin actually spiked in the serum samples.
Experimental Results 1. Characterization of Reduced GO Electrode
[0082] Although GO can be electrochemically reduced in a wide pH range of 1.5 to 12.5, optimal pH conditions for the medium are essential to ensure that the rGO surface has excellent electrocatalytic properties. Reduced GO films were prepared through cyclic voltammetry for a potential range of −1.5 to 0 V in buffer solutions of various pH conditions.
[0083]
[0084] As a result of Raman spectroscopy measurement for quantitative analysis of rGO in
Experimental Results 2. Characterization of rGO/PEDOT:PSS/Nafion Electrode
2.1. Morphological Analysis
[0085]
[0086] Chemical transformation was confirmed by irradiating the fabricated GO, rGO, rGO/PEDOT:PSS, and rGO/PEDOT:PSS/Nafion electrodes with FT-IR.
[0087] To investigate the presence of different material layers in the rGO/PEDOT:PSS/Nafion electrode, XPS distribution analysis was performed for Au4f, C1s, F1s, O1s and S2p level regions.
2.2. Electrochemical Properties
[0088] To investigate the electrochemical performance of the fabricated working electrode, interfacial impedances and cyclic voltammetry of Au, GO, rGO, rGO/PEDOT:PSS, and rGO/PEDOT:PSS/Nafion electrodes were measured in a 0.1 M PBS solution (pH 7.4), and the results are shown in
[0089] PEDOT:PSS exhibited an extended current response indicating an increased number of electrochemically active sites. In the measured CV curves, the CSC values implying the accumulated charges gradually expanded in the order of Au<GO<rGO<rGO/PEDOT:PSS<rGO/PEDOT:PSS/Nafion, and exhibited values of 0.15, 1.14, 13.3, 22.6, and 15.6 mC/cm.sup.2, respectively. The rGO/PEDOT:PSS electrode was strengthened to have higher capacitance values after electrochemical reduction and deposition.
[0090] As shown in
Experimental Results 3. Effects of Scan Rate and pH
[0091] The effects of the scan rates evaluated using the CV curves were shown in
[0092] The effect of pH on the oxidation of serotonin in a sensor including the rGO/PEDOT:PSS/Nafion electrode was investigated with DPV in the pH range of 5 to 9.
Experimental Results 4. DPV Responses of rGO/PEDOT:PSS/Nafion Electrode to Dopamine and Serotonin
[0093] As shown in
[0094] To confirm the selective detection of dopamine and serotonin, the concentration of one species was fixed and the concentration of the other species was changed. Simultaneous detection of two analytes was performed by simultaneously changing the concentration of one species in the prepared mixture. As shown in
[0095] Compared with previous studies, the sensor according to the present disclosure exhibited excellent distinctiveness in the simultaneous response to dopamine and serotonin. The improved performance of the present disclosure may be due to the high catalytically active site of rGO/PEDOT:PSS/Nafion based on the surface, large surface area, and excellent electron-conducting support material of negatively charged Nafion.
Experimental Results 5. Selectivity
[0096] The presence of interference is an important parameter determining the selectivity of the rGO/PEDOT:PSS/Nafion electrode for serotonin detection. The coexistence of serotonin and other interfering species may induce mixed response currents due to their close oxidation potential.
[0097] Therefore, the selectivities of the sensor including the rGO/PEDOT:PSS/Nafion electrode were investigated with DPV oxidation current responses of serotonin (1 μM).
TABLE-US-00001 TABLE 1 Concentration of interfering Concentration Interfering substance of serotonin Serotonin DPV's Peak current of substance added (μM) (μM) potential (V) serotonin (μA) Ascorbic acid (AA) 1000 1 0.250 65.72 Uric acid (UA) 50 1 0.247 65.95 Glucose 100 1 0.251 65.85 Epinephrine (EP) 10 1 0.248 65.73 Norepinephrine 10 1 0.252 65.86 (NE)
[0098] According to Table 1, the peak oxidation currents of serotonin were maintained at 65 μA, and it was found that even if interfering substances with higher concentrations were present, the responses of serotonin DPV were not significantly interfered. Particularly, the oxidation potential of serotonin at 1,000 μM of ascorbic acid did not shift at 0.25 V due to repulsion from the negatively charged Nafion surface. Based on the above results, it was confirmed that the sensor including the rGO/PEDOT:PSS/Nafion electrode according to the present disclosure has higher anti-interference abilities for ascorbic acid, uric acid, glucose, epinephrine, and norepinephrine in the detection of serotonin. This means the excellent selectivity of the present disclosure for serotonin.
Experimental Results 6. Reproducibility and Stability of Sensor Including rGO/PEDOT:PSS/Nafion Electrode
[0099] As shown in
Experimental Results 7. Analysis of Real Serum Samples
[0100] In order to demonstrate that the sensor including the rGO/PEDOT:PSS/Nafion electrode according to the present disclosure can be used for clinical detection, a sensor including the rGO/PEDOT:PSS/Nafion electrode was tested, and spiked real serum samples were used to compare recovery rates.
[0101] The recovery rates were 93.3% to 101.8% (RSD, n=3) based on the detection of serotonin in human serum (Table 2), and the sensor including the rGO/PEDOT:PSS/Nafion electrode effectively detected serotonin from human serum samples.
TABLE-US-00002 TABLE 2 Sample Spiked (μM) Found (μM) Recovery (%) RSD (%)(n = 3) Serum 1 0.05 0.0485 96.9 2.2 Serum 2 0.1 0.0972 97.2 2.1 Serum 3 0.5 0.4784 95.6 4.3 Serum 4 1 0.9615 96.2 6.5 Serum 5 5 4.9124 98.2 5.4 Serum 6 10 9.3325 93.3 5.9 Serum 7 25 24.9232 99.6 4.8 Serum 8 50 50.9085 101.8 6.6
[0102] Interestingly, the above results showed excellent recovery rates for 0.05 to 5 μM, indicating that the sensor according to the present disclosure can efficiently detect even low levels of serotonin in human serum, and reproducibility and feasibility are also very high. In addition, in order to investigate the detection of serotonin by the sensor including the rGO/PEDOT:PSS/Nafion electrode in the presence of dopamine, dopamine and serotonin (0.1 to 5 μM) were added to serum samples (Table 3).
TABLE-US-00003 TABLE 3 RSD (%) Spiked (μM) Found (μM) Recovery (%) (n = 3) Sample DA 5-HT DA 5-HT DA 5-HT DA 5-HT Serum 1 0.1 0.1 0.0933 0.0961 93.3 96.1 2.3 2.5 Serum 2 0.5 0.5 0.4602 0.4456 92.4 89.1 2.4 3.3 Serum 3 1 1 0.9188 0.9652 91.9 96.5 3.5 2.7 Serum 4 5 5 4.4708 4.7467 89.4 94.9 4.0 4.9
[0103] The recovery rates of dopamine and serotonin were 89.4 to 93.3% and 89.1 to 96.1%, respectively, and the relative standard deviations (RSD) of three replicates were less than 5%. Therefore, the sensor including the rGO/PEDOT:PSS/Nafion electrode showed an excellent recovery range in undiluted serum samples, and this suggests that the present disclosure is suitable for detection of dopamine and serotonin in actual sample analysis.
[0104] Although Examples have been described with reference to the limited drawings as described above, those skilled in the art may apply various technical modifications and variations based on the above description. For example, although the described techniques are performed in an order different from the described method, and/or the constituent elements such as the described system, structure, apparatus, circuit, etc. are coupled or combined in a form different from the described method, or replaced or substituted by other constituent elements or equivalents, appropriate results may be accomplished.
[0105] Therefore, other embodiments, other Examples, and equivalents to the patent claim scope also belong to the scope of the claims to be described later.